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INTRODUCTION:  A bloodless  surgery  can  be desirable  also  for  non  Jehovah’s  witnesses  patients,  but
requires  a team  approach  from  the  very  ﬁrst assessment  to  ensure  adequate  planning.
PRESENTATION  OF  THE  CASE:  Our patient,  a  Jehovah’s  witnesses,  was  scheduled  for right  lower  lobectomy
due  to pulmonary  adenocarcinoma.  Her  ﬁrm  denies  to  receive  any  kind  of  transfusions,  forced  clinicians
to  a  bloodless  management  of  the case.
DISCUSSION:  Before  surgery  a meticulous  coagulopathy  research  and  hemodynamic  optimization  are use-
ful  to prepare  patient  to operation.  During  surgery,  controlled  hypotension  can  help to obtain  effective
hemostasis.  After  surgery,  clinicians  monitored  any  possible  active  bleeding,  using  continuous  noninva-leeding monitoring
horacic surgery
ase report
sive  hemoglobin  monitoring,  limiting  the blood  loss  due  to serial  in vitro  testing.  The  optimization  of
cardiac  index  and  delivery  of  oxygen  were  continued  to  grant  a fast  recovery.
CONCLUSION:  Bloodless  surgery  is  likely  to gain  popularity,  and  become  standard  practice  for  all patients.
The  need  for  transfusion  should  be targeted  on  individual  case, avoiding  strictly  ﬁxed  limit  often  leading
to  unnecessary  transfusion.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Our patient, a Jehovah’s witnesses, was scheduled for right
ower lobectomy due to pulmonary adenocarcinoma. Her ﬁrm
eny to receive any kind of transfusions, forced clinicians to a
loodless management of the case. A bloodless surgery can be
esirable also for non Jehovah’s witnesses patients, but requires
 team approach from the very ﬁrst assessment to ensure adequate
lanning. Before surgery a meticulous coagulopathy research and
emodynamic optimization are useful to prepare patient to oper-
tion. During surgery, controlled hypotension can help to obtain
ffective hemostasis. After surgery, clinicians monitored any pos-
ible active bleeding, using continuous noninvasive hemoglobin
onitoring, limiting the blood loss due to serial in vitro testing. The
ptimization of CI and DO2 were continued to grant a fast recovery.∗ Corresponding author.
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arlo.bergaminelli@libero.it (C. Bergaminelli), mrnespoli@hotmail.it (M.R. Nespoli),
aesposito15@gmail.com (M.  Esposito), dario.mattiacci@libero.it (D.M. Mattiacci),
orcio.ant@libero.it (A. Corcione), salvatorebuono48@gmail.com (S. Buono).
ttp://dx.doi.org/10.1016/j.ijscr.2016.04.024
210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/).2. Case presentation
A Jehovah’s witness patient (female, 71-year-old, BMI  23)
came to our thoracic surgery ward to undergo right lower lobec-
tomy due to pulmonary adenocarcinoma. Patient had history
of strong smoking habits (smoking pack years 79) and hyper-
tension in non pharmacological treatment. She had cough with
sputum for two month and dyspnea after exercise (METS >4), she
underwent a computed tomography (CT) scan which showed a
2.6 × 2.0-cm mass in the right lower lobe of the lung with no
signiﬁcant mediastinal lymph node enlargement. Positron emis-
sion tomography-computed tomography (PET-CT) reported a high
metabolic mass with possible large lumps in the right lower lobe
lung 2.6 × 2.0 cm in size (SUV 5.5).
Once proposed for surgery, patient ﬁrmly deny the possibil-
ity to receive transfusions of whole blood, packed erythrocytes,
platelets, white cells or plasma. She rejected auto transfusion with
blood pre-deposit too. Surgeons, anesthesiologists and operating
theatre staff discussed the cases and decide how to manage the
patient: pre operative assessment provided spirometry test (FEV1
70%, DLCO 54%) and Cardio Pulmonary Exercise Test (VO2 max  13.7,
Slope VE/VCO2 32). Arterial Blood Gas (ABG) showed: pH 7.39 pCO2
42 pO2 75 Lat 0.4HCO3 25.4 BE 0.4 SpO2 97.5. Cardiac status was
rated as good by cardiologist that stated administration of biso-
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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rolol to control hypertension and required a strict blood pression
easurement to optimize therapy. Laboratory test showed a mild
ormocitic anemia (Hb 10.5 g/dl) with no B12 or iron-deﬁciency.
atient was extensively questioned for previous suspect bleeding
pisodes and underwent coagulation test screen (Plt 324000/ul; PT
7.2 s; PA 92%; INR 1.5). Also thromboelastography (TEG) was  per-
ormed, with no report of abnormalities in platelet function, clot
trength, and ﬁbrinolysis (R: 6 min; K: 3 min; -Angle: 63◦; MA:
9 mm;  LY 30%: 6%).
Informed consent was signed by the patient after having con-
idered and discussed about the speciﬁc risks and beneﬁts of any
rocedure including the added risk of blood refusal.
The day before surgery, patient was moved to post anesthesia
ntensive care unit (PACU): a center venous catheter was placed
n right internal jugular vein with ultrasound guidance and left
adial artery cannulation was performed. 24 h pre-surgery ﬂuid
dministration was evaluated using a VigileoTM monitor (Edwards
ifesciences; One Edwards Way  Irvine, CA 92614) with FloTrac and
reSep sensor, to optimize Cardiac Index (CI), Stroke Volume (SV),
entral Venous Oxygen Saturation (ScVO2) and, consequentially,
elivery Oxygen (DO2).
Surgeon decided to approach the lobectomy in Video Assisted
horacic Surgery (VATS), to minimize blood loss. Operating room
onitoring was: continuous ECG, invasive blood pressure (iBP),
ulsoxymetry, INVOS cerebral/somatic oximetry (Covidien; 710
edtronic Parkway Minneapolis, MN  55432-5604), Bispectral
ndex (BIS), TOF-Watch and VigileoTM (CI; SV; continuous ScVO2).
arget Controlled Infusion Total IntraVenous Anesthesia (TIVA-TCI)
as performed with propofol and remifentanil, muscle relaxation
as obtained with rocuronium and One Lung Ventilation (OLV)
as achieved with Double Lumen Tube 37 Fr and checked with
beroptic bronchoscopy. During surgery a controlled hypotension
ith a reduction of mean arterial pressure (MAP) to 50–65 mm Hg
as performed with appropriate dose of propofol and remifentanil.
lood pressure is returned to normal prior to complete the oper-
tion to grant adequate hemostasis when the patient returns to a
ormotensive state.
Surgery lasted 153 min  in VATS three portal approach. Dissec-
ion was carried out with endopeanuts and meticulous hemostasis
as obtained with LigaSureTM (Covidien; 710 Medtronic Park-
ay Minneapoli, MN  55432-5604) blunt tip. Major vessels were
ut between clips. TabotampTM ﬁbrillar (Ethicon, Route 22 ovest
omerville, NJ 08876, USA) was used for hemostasis in mediastinal
ymphadenectomy area. Perfect hemostasis was  double checked
ith repeated saline solution washing. Overall blood loss was
40 ml.  At end of surgery, two thoracic drainage tubes were placed.
ost-operative analgesia was granted by levobupivacaine contin-
ous infusion via thoracic epidural catheter, and PCA enodvenous
orphine, no NSAIDs were used.
Patient was  moved to PACU still under general anesthesia, CI,
nd SV was evaluated again to optimize cardiac output and grant
dequate DO2. Postoperative blood test samples were sent in pedi-
tric tubes (Hb: 8.3 g/dl; Plt 297000/ul; PT 33 s; PA 79%; INR 1.5)
nd Continuous Noninvasive Hemoglobin Monitoring (CNHM) was
erformed with Radical-7 Pulse CO-Oximeter (Masimo®, Irvine, CA,
SA), to minimize blood loss from laboratory testing. Patient awake
uiet and painless.
No bleeding signs were recorded during the 48 h PACU stay: the
verall chest drainage was 400 ml  sierohematic ﬂuid, Hb was never
ower than 8.1 g/dl according to CNHM, and there were not any
emodynamic alterations. Patient was moved to thoracic surgery
ard and after four days she was dismissed.
. Discussion
Jehovah’s witnesses have been in Italy since 1903. With 248′783
bservant, they represent the second religion of the country accord-PEN  ACCESS
gery Case Reports 23 (2016) 116–119 117
ing to Italian New Religion Study Center (CESNUR) [1]. The beliefs
of Jehovah’s Witnesses are based on the Bible teachings of Charles
Taze Russell: transfusion of whole blood, packed red cells, platelets,
white cells or plasma are unacceptable health treatments [2]; even
predonation of blood for the purposes of later autotransfusion (pre-
deposit) is unacceptable [3] although many Jehovah’s witnesses
will accept peri and postoperative autologous procedures such as
acute normovolaemic hemodilution or cell salvage machines [4,5].
In this case, the patient received a meticulous pre-operative
evaluation to investigate bleeding disorders or coagulation defects.
Accurate anamnesis and coagulation screen test can point out the
most of clotting disorder, but TEG can evaluate the dynamic inter-
action of clotting factors and platelets, indicating an overall clot
quality, becoming popular monitoring for hemostasis and transfu-
sion management in major surgery [6]. Patient was asked for any
medications that may  increase blood loss. After clinical investiga-
tions, clinicians reported no increase in standard surgery bleeding
risk.
Laboratory test, moreover, showed a mild normocitic anemia
(Hb 10.5 g/dl) with no B12 or iron-deﬁciency. One of the most used
method to improve haemopoiesis in Jehovah’s witnesses is the use
of erythropoietin [7], but in Italy there is no indications to this use
according to Italian Drug Agency (AIFA) [8]. Pre-existing cardiac
or respiratory disease must be investigated, and optimized. Our
patient had hypertension in non pharmacological treatment, and
poor blood pression control in surgery is of major clinical impor-
tance resulting in possible aggravation of bleeding [9]. To improve
tissue oxygenation, although the mild anemia, patient was moni-
tored with VigileoTM. Optimizing ﬂuid administration using CI, SV
and ScVO2 parameters, will help to maximize cardiac output and,
therefore, oxygen delivery [10,11].
The surgeon mini-invasive video-assisted approach causes
minor blood loss [12–15] and, even in case of emergency
thoracotomy conversion, rate of life-threatening perioperative
complications or perioperative mortality did not increase [16].
No intraoperative blood salvage device was  arranged because,
although it has been demonstrated that a high percentage of
patients presenting for cancer surgery actually have already cir-
culating tumor cells, is a question yet left unanswered if adding
tumor cells into the circulation could worsen prognosis [17,18].
During surgery, one of the best and safest way to prevent excessive
bleeding, is hypotensive anesthesia (MAP to 50–65 mmHg) using
propofol and remifentanil, to reduce the extent of intraoperative
blood loss [18,19].
To reduce iatrogenic blood loss due to intensive post-operative
laboratory tests, highly associated to anemia, blood test samples
were sent in pediatric tubes (Hb: 8.3 g/dl; Plt 297000/ul; PT 33 s;
PA 79%; INR 1.5) [20]. Another way to reduce need for blood sam-
ples, without losing accuracy and continuous control, is to monitor
hemoglobin with noninvasive device: the use of CNHM has strong
merits in monitoring trend and is an useful alternative to serial
in vitro testing, especially when reducing iatrogenic blood loss,
conserving patient blood volume [21–23].
A bloodless surgery can be desirable also for non Jehovah’s wit-
nesses patients, but requires a team approach from the very ﬁrst
assessment to ensure adequate planning. Before surgery, we inves-
tigated any possible details leading to increasing bleeding risk and
optimized the patient hemodynamic to obtain the maximum oxy-
gen delivery, even with mild anemia. During surgery, the controlled
hypotension and a very conscientious hemostasis are mandatory,
especially if you can’t use a cell salvage system. After surgery, clin-
icians have to individuate any possible active bleeding, using non
invasive but accurate monitoring, limiting the iatrogenic blood loss
due to serial in vitro testing. The optimization of CI and DO2 have
to be continued to grant a fast recovery, especially in anemic state.
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According to Frank-Sterling law, increased volume of blood
tretches the ventricular wall, causing cardiac muscle to
ontract more forcefully, thus the ﬂuidic optimization guarantees
n increase of the CI. The amount of blood the heart pumps through
he circulatory system in a minute is one of the main determinant of
O2 while Hb amount has, indeed, a supporting role. In the medical
iterature there are studies that have shown the mismatch between
ransfusions and increased DO2 and VO2. This seems to suggest a
redominant role of the CI in the maintenance of adequate DO2 and
O2 may  redeﬁne the limits and traditional criteria for the use of
lood derivatives [24,25].
Improving DO2 has been demonstrated in the perioperative
eriod to reduce both morbidity and mortality enhancing wound
ealing and reducing infection risk [26,27].
Rapid plasma volume expansion can prevent haemodynamic
uctuation during anaesthesia induction and maintain the balance
etween oxygen supply and oxygen consumption during gastroin-
estinal surgery improving the oxygen delivery [28].
. Conclusion
Facing the refusal of a Jehovah’s Witness to accept a blood trans-
usion, when absolutely necessary for vital reasons, is probably one
f the most frustrating situations in medical wards. There may  be
 furious temptation to overcome this refusal when the situation
ecomes critical or irreversible [29] Although they do not reject
ither organ transplantation or red blood cell-depleted stem cell
ransplants, it can be questioned as to whether they are likely
o accept induced pluripotent stem cells or mesenchymal stem
ell-derived red blood cells, currently one of the most promising
lternatives [30]. The bloodless medicine was initially developed
o provide necessary treatment to patients of this faith, but admin-
stering bloodless care to Jehovah’s Witnesses, valuable lessons can
e learned about the transfusion avoidance strategies. Intensive
erioperative care of patients aiming to avoid blood transfusion
nd improve patient outcomes are desirable, considering blood
tores are decreasing and costs are increasing [31]. These princi-
les are likely to gain popularity, and become standard practice for
ll patients, considering that preliminary studies do suggest that
loodless practices should be considered for use in all patients,
ecause the beneﬁts appear to be substantial and the risks minimal
32,33]. The need for transfusion should be targeted on individ-
al case, avoiding strictly ﬁxed limit often leading to unnecessary
ransfusion.
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